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The EMHG first published its protocol for an in vitro contracture 
test (IVCT) in 19841 and this has ever since formed the bedrock 
of clinical diagnosis and phenotyping. In 20152 the EMHG 
published the updated guidelines for investigation of malignant 
hyperthermia susceptibility. Evidently the rigour of the IVCT 
stood the test of time and was used in more than 10 000 
individuals worldwide to define their MH risk, representing an 
example of preventative medicine and improved patient safety.
The IVCT is a clinically useful and robust test3 that is sensitive 
and specific. The initial point estimate for specificity of 94% 
could possibly be explained by the use of atrophied muscle, 
because muscle sampled during ipsilateral joint arthroplasty was 
included.3 The reported point estimate for sensitivity of the IVCT 
was 99%. On closer examination of the single patient (case 4) 
who reduced the sensitivity from 100% to 99%, it was found that 
the authors misapplied the Larach Clinical Grading Scale (LCGS)4 
which specifically excludes rigidity on emergence of general 
anaesthesia as an indicator of MH. The LCGS score for this patient 
should have been 35, therefore excluding the patient from the 
category of “almost certain” MH used to determine the sensitivity 
of the test. This was possibly a case of iatrogenic hyperthermia 
and febrile convulsion in an infant who had received atropine 
before surgery and overly enthusiastic warming during surgery.
The robustness of the IVCT was further evident from its use 
to phenotype members of MH families in molecular genetic 
studies, firstly with the linkage analysis that identified RYR1 as 
the major locus implicated in MH5 6, and later with the second 
locus CACNA1S7 8 providing further evidence for the involvement 
of interacting gene products. STAC3 is the most recent gene 
associated with MH.9 A homozygous STAC3 mutation has been 
linked to Native American myopathy and MH susceptibility in 
one Native American family.10 
The complex nature of the genetics of MH, which would not have 
been realized without the IVCT, has been confirmed further by 
early results of next-generation sequencing in MH families.11 12 
Once an MH-causative mutation has been identified in an MH 
index patient, the family can be screened for this mutation and 
all the relatives carrying this mutation will be considered MH 
susceptible. Unfortunately 50% of MHS individuals do not carry 
potentially pathogenic variants in the known MH-associated 
genes, resulting in a rather low sensitivity of MH genetic testing.13
Currently the presence of rare variants in RYR1, CACNA1S and 
STAC3 also has a low specificity. While there are more than 200 
reported RYR1 variants associated with MH, only 42 RYR1 and 2 
CACNA1S variants are accepted as MH causative (www.emhg.org) 
and can be used in diagnostic genetic testing for MH. It is also 
important to note that these causative mutations are population 
specific and the patients from African origin are most likely to be 
negative for these causative mutations described in Caucasian 
patients. If the specific variants in the African population have 
been identified, it needs to be shown to produce functional 
changes compatible with a pathogenic role in appropriate 
model cell systems.14 Currently we do not have a laboratory in 
South Africa that does functional studies and calcium handling.
Because of the complex nature of MH genetics, a negative 
genetic test result cannot be used to rule out MH susceptibility 
and patients with negative genetic results should be offered in 
vitro contracture testing to confirm their MH-negative status.
Before the establishment of in vitro contracture testing15, 
persistently raised serum creatine kinase (CK) concentration was 
documented in association with MH susceptibility and proposed 
as a diagnostic test. The utility of resting CK concentration is, 
however, limited because of a lack of sensitivity and specificity.16 
However, in patients with so-called idiopathic hyperCKaemia, 
investigation of MH susceptibility may be warranted after other 
causes have been excluded by a full neurological examination.17 
As with patients with rhabdomyolysis, the neurologist should 
liaise with an MH testing centre, where any muscle biopsy should 
be carried out to also do IVCT and histology.
Criteria for patient referral
The most common reasons for referral for investigation of MH 
susceptibility2 are listed in Table 1.
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Table 1. Patients to be referred to the MH diagnostic centre for 
investigation of MH susceptibility.
Reasons for referral for investigation of MH susceptibility
1. Family history of MH.
2. Adverse reaction to general anaesthesia where a trigger 
agent has been used, involving any combination of signs 
of increased metabolism (unexplained increase in carbon 
dioxide production, tachycardia, temperature increase), 
muscle rigidity, rhabdomyolysis, disseminated intravascular 
coagulation or death. Initial signs should be evident within  
60 minutes of discontinuation of anaesthesia.
3. When MH cannot be excluded after LCGS calculation of 
adverse anaesthetic event.
4. Family history of unexplained perioperative death.
5. Postoperative rhabdomyolysis after exclusion of other 
myopathies.
6. Exertional rhabdomyolysis, recurrent rhabdomyolysis or 
persistently raised serum creatine kinase concentration where 
no cause has been identified after neurological work-up 
(idiopathic hyperCKaemia).
7. Exertional heatstroke requiring hospital admission, where 
known predisposing factors have been excluded.
8. Myopathy and detection of an uncharacterised, rare, 
potentially pathogenic RYR1 variant like central core disease, 
multiminicore disease, congenital centronuclear myopathy, 
nemaline myopathy, congenital fibre-type disproportion, 
King-Denborough syndrome, benign Samaritan congenital 
myopathy, atypical periodic paralysis and statin myopathies.9
The diagnostic pathway for MH susceptibility
The diagnostic pathway for investigation of MH susceptibility is 
explained in the following flow chart published by the EMHG.2
Reproduced from Reference 2 with permission from Elsevier 
Science.
The EMHG recommendations for minimum age and weight for 
children undergoing the IVCT is 10 years and 30 kg.2 The biopsy 
should be performed on the quadriceps muscle, either the vastus 
medialis or vastus lateralis, using regional or trigger-free general 
anaesthetic techniques. Avoid any local anaesthetic infiltration 
of the muscle tissue. As the IVCT is a biophysical test and 
physical conditions around the muscle biopsy directly impact 
on the viability of the muscle specimen, muscle biopsy should 
be done at the MH centre where the muscle can be transported 
in carboxygenated Krebs-Ringers solution and the time from 
biopsy to completion of the test should not exceed five hours. 
The requirements for muscle specimen dimensions are 
20–25 mm in length between ties, with a thickness of 2–3 mm. 
The weight of the specimen should be 100–200 mg.
The updated laboratory diagnostic classification is as follows:
• MHShc : a caffeine threshold at the caffeine concentration of 
2.0 mmol litre-1 or less in at least one caffeine test, and a 
halothane threshold concentration at 0.44 mmol litre-1 or less 
in at least one halothane test.
• MHSh : a halothane threshold concentration at 0.44 mmol litre-1 
or less in at least one halothane test and a caffeine threshold at 
a caffeine concentration of 3 mmol litre-1 or more in all caffeine 
tests.
• MHSC : a caffeine threshold at a caffeine concentration of 
2.0 mmol litre-1 or less and a halothane threshold concentration 
above 0.44 mmol litre-1 in all halothane tests.
• MHN: a caffeine threshold at a caffeine concentration of 3 mmol 
litr-1 or more in all caffeine tests and a halothane threshold 
concentration above 0.44 mmol litre-1 in all halothane tests.
The MHE (Malignant Hyperthermia Equivocal) classification is no 
longer used and MH susceptibility is indicated by MHShc, MHSh 
and MHSc, and patients not susceptible to MH by MHN.
The most fundamental role of MH diagnostics is to be conservative 
in applying the MHN diagnosis because a false-negative 
diagnosis is most likely to have disastrous consequences. The 
evidence is that a laboratory diagnosis of MHN by IVCT provides 
a high degree of security if carried out in an EMHG-accredited 
laboratory. The EMHG quality assurance program assures that an 
accredited laboratory conducts the tests according to the EMHG 
published protocol, assures that specimens fulfill the viability 
criteria, and guarantees control of the test bath constituents 
and conditions, including concentration measurements by a 
reference laboratory. While the offspring of a patient who tested 
MHN cannot inherit MH susceptibility from that parent, it is still 
possible that they may be susceptible by transmission from the 
other untested parent or through a de novo genetic mutation. The 
probability of either of these events is less than the population 
prevalence of MH susceptibility, which is 1:15 000.
Activated charcoal filters
Along with the development of the newer anaesthetic 
machines came more challenges in preparation of the theatre 
for malignant hyperthermia susceptible patients18. Increased 
amounts of plastic and rubber parts on the internal circuit of new 
anaesthetic workstations that adsorb anaesthetic vapour serve 
as a reservoir of anaesthetic vapour, and after lengthy purging 
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it is evident that because of the rebound phenomenon, residual 
emission of anaesthetic vapour still occurs. It is also impossible 
to give a fixed time for purging to create a safe, clean machine as 
the amount of vapour absorbing parts in each make and model 
of anaesthetic machine differs. Therefore, the time it takes to 
purge the machine to get the vapour concentration in the fresh 
gas system to less than 5 ppm differs as well. It is recommended 
that after lengthy purging, fresh gas flow remains above 
10 L/min throughout the anaesthetic. 
Alternatively, activated charcoal filters (ACFs) can be used to 
prepare the anaesthetic machine to deliver a trigger-free general 
anaesthetic to MH susceptible patients or to patients with 
increased risk of developing an MH crisis.19 ACFs can clean the 
anaesthetic machine in 90 seconds, irrespective of the specific 
make or model.
Recommendations on the use of activated charcoal filters 20 are 
summarised in Table 2.
Table 2. Recommendations on the use of activated charcoal filters 
in preparing an anaesthetic machine for a malignant hyperthermia 
susceptible patient.
Recommendations
1. Remove vaporisers from the anaesthetic machine.
2. Flush the circuit for 90s with oxygen or air @ 10 l/min using the 
ventilator with a 2 litre test lung attached.
3. Change the full breathing circuit and soda lime while 
maintaining flushing @ 10 l/min (the ventilator is left 
unchanged).
4. Insert ACFs on both inspiratory and expiratory ports of the 
breathing circuit.
5. Maintain FGF of 10 l/min for 90 minutes from the beginning of 
the anaesthetic.
6. After 90 minutes it is safe to reduce the FGF to 3 l/min.
7. Then ACFs can be used at 3 l/min until a total of 12 hours has 
elapsed from the commencement of the anaesthetic.
8. After 12 hours ACFs need to be replaced.
9. ACFs are single-use items.
10. Single ACF can be placed in only the inspiratory limb but if 
misplaced accidentally in expiratory limb, it will be completely 
ineffective. Because of this potentially dangerous situation it is 
recommended that ACFs be used as a pair, one in each limb.
Reproduced from Reference 20 with the permission of the 
Author.
Conclusion
Being able to determine potential malignant hyperthermia 
patients’ real risk after so many years without an IVCT laboratory 
definitely improves the standard of care in South Africa. 
Additionally, the in vitro contracture testing facility could also 
be contributing to the DNA mapping of population groups with 
undefined causative MH variants. The availability of activated 
charcoal filters gives anaesthesiologists an option of expediting 
and improving anaesthetic machine preparation for malignant 
hyperthermia susceptible patients.9 20
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